Authors
Latest:
Connor Forbes, MD, on trends in surgical procedures for BPHMIST utilization increased from 7% in 2015 to 51% in 2022 among men aged 50 to 54.
Latest:
Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUIThe CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.
Latest:
Juan Andino, MD, highlights SUO session on telehealth in urology“Without Congressional action, all the progress that has been made—the new normal, so to speak—that patients, physicians, and providers alike have become used to, is at risk of potentially going back to pre-pandemic, 2019 levels,” says Juan J. Andino, MD, MBA.
Latest:
Vikram Narayan, MD, on embracing thoughtful tech adoptionVikram M. Narayan, MD, FACS, offers advice for institutions that are considering investments in technology to improve clinical workflows.
Latest:
Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
Latest:
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Latest:
Is a medical scribe right for your practice?“Regardless of the size of the practice, medical scribes are a valuable resource for health care providers, helping to streamline workflow and coordinate patient care,” writes Brian Hudson.
Latest:
Experts discuss review of the microbiome and bladder cancer"My biggest hope for people reading this review is to understand that there are some golden opportunities for research," says Laura Bukavina, MD, MPH, MSc.
Latest:
Diagnostic stewardship for urinary tract infection: A snapshot of the expert guidanceUrinary tract infections (UTIs) are among the most common human infections. But the urine culture, the cornerstone for laboratory diagnosis of UTI, is imperfect.
Latest:
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MDExplore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
Latest:
Combo of cabozantinib and pembrolizumab shows promise in frontline urothelial carcinomaResults from the phase 2 PemCab trial showed that the first-line combination elicited promising antitumor activity with tolerable toxicity in patients with advanced urothelial carcinoma, including those who were cisplatin ineligible.
Latest:
Mark Edney, MD, highlights pending telehealth legislation"The relaxation of the restrictions that started during COVID are critically important for continued access," says Mark T. Edney, MD.
Latest:
Pearls & Perspectives: Urology's role in GLP-1 RA treatments, with Hossein Sadeghi-Nejad, MD, and Nathalie Eid, BAThis episodes explores the evolving role of GLP-1 medications in testosterone management and their impact on male sexual health and fertility.
Latest:
FDA grants Regenerative Medicine Advanced Therapy designation to ALLO-316 for RCCThe RMAT designation is supported by interim data from the ongoing phase 1 TRAVERSE trial.
Latest:
Final Thoughts and Clinical Trials in NMIBCExperts share their concluding thoughts on the recent progress and future outlook for the treatment of non–muscle-invasive bladder cancer (NMIBC).
Latest:
Expert highlights program addressing disparities in prostate cancer careIn this interview, Mary-Ellen Taplin, MD, discusses disparities in prostate cancer care and a unique initiative aiming to alleviate those disparities.
Latest:
Scott Tagawa, MD, on the mechanism of action for 177Lu-TLX591 in mCRPC“If there's enough radiation, then the cells can't repair themselves and die because of the radiation,” says Scott T. Tagawa, MD, MS, FACP, FASCO.
Latest:
Data support use of 18F-PSMA-1007 PET/CT in prostate cancer“These findings support the use of 18F-PSMA-1007 PET/CT in the preoperative workflow of intermediate-and high-risk tumors,” said Nikhile Mookerji, MD.
Latest:
How to assemble a Thompson Retractor for midline transabdominal retroperitoneal surgeryThe patient presented with a large right renal mass who elected for right radical nephrectomy with possible inferior vena cava.
Latest:
Pearls & Perspectives: Martin Kathrins, MD, on MED3000 and learning from failed trialsKathrins discusses the intricacies of leading a clinical trial and why "negative" trials are important to informing care strategies.
Latest:
Joshua Heiman, MD, on phentermine plus topiramate for uric acid stone preventionJoshua M. Heiman, MD, details key findings from the POuND OUT study.
Latest:
Mina Fam, MD, on managing expectations around testosterone replacement therapyMina M. Fam, MD, discusses some of the common misconceptions that patients have when seeking testosterone replacement therapy.
Latest:
Amar Kishan, MD, highlights ongoing research on reducing toxicity in SBRT"For the MIRAGE trial specifically, we're going to continue following patients and we'll look at [data at] 5 years as well," says Amar U. Kishan, MD.
Latest:
Diet and interstitial cystitis: A urologist’s view"There are some very strict IC diets that have been published, and I've had a handful of patients who have really found them helpful," says J. Quentin Clemens, MD, MSCI.
Latest:
Tips for successfully mentoring other physiciansHere are some helpful hints for launching your physician mentor-mentee relationship.
Latest:
Sima Porten, MD, on gene-environment interactions in bladder cancer developmentSima P. Porten, MD, MPH, discusses the need to better understand how genetic makeup influences how individuals process environmental toxins.
Latest:
Episode 3 Video: Managing Overactive Bladder: From Dual Diagnoses to Geriatric ChallengesWayne Kuang, MD; and Matt T. Rosenberg, MD, discuss how overactive bladder presents with distinct pathophysiological mechanisms between genders, requires different diagnostic approaches when distinguishing from benign prostatic hyperplasia in men, impacts quality of life in older adults, benefits from early primary care intervention, and necessitates improved patient advocacy and educational initiatives for optimal management outcomes.
Latest:
Future patient profiles for TARA-002An expert summarizes that although it is currently too early to determine optimal sequencing among bladder cancer therapies, emerging strategies involving combination treatments and immune system priming show promise for enhancing efficacy, particularly in high-risk patients, underscoring the need for further research to guide personalized treatment decisions.
Latest:
Dr. Lara reviews the evolving systemic therapy paradigm in renal cell carcinoma“The question of who is a candidate for active surveillance is hard to answer because this is a bedside, gut decision," says Primo Nery Lara, Jr, MD.
Latest:
Chad Reichard, MD, on the Expanded Access Program for recombinant BCG"This certainly does feel like the beginning of the light at the end of the tunnel coming out of the BCG shortage," says Chad A. Reichard, MD.
